Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2 relapsed or refractory inflammatory breast cancer

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1065-1073

  Kaufman, B ^a   Wu, Y ^b   Amonkar, M M ^c   Sherrill, B ^b   Bachelot, T ^d   Salazar, V ^c   Viens, P ^e   Johnston, S ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (United States)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

HER2; Inflammatory breast cancer; Lapatinib; Quality of life

Indexed keywords

LAPATINIB;

ADULT; AGED; ARTICLE; BREAST CANCER; BRIEF PAIN INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY BREAST CANCER; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; POST HOC ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; PAIN; QUALITY OF LIFE; QUINAZOLINES;

EID: 77951051621     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003680323     Document Type: Article

References (27)

1. Liauw S, Benda R, Morris C, et al. Inflammatory breast carcinoma: outcomes with trimodality therapy for nonmetastatic disease. Cancer 2004;100:920-928
2. Giordano SH, Hortobagyi GN. Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res 2003; 5:284-288
3. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 1998;82:2366-2372
4. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003;8:141-148
5. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-429
6. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-4074
7. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594
8. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-3617
9. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-1655
10. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593
11. Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer 2008;99:711-715
12. Zhou X, Cella D, Cameron D, et al. Lapatinib plus capecitabine versus cape-citabine alone for HER2\+ (ErbB2\+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-589
13. Burris III HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;3:5305-5313
14. Jones SF, Hainsworth JD, Spigel DR, et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009). J Clin Oncol 2004; 22(Suppl):147s, (abstr 2083)
15. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2\+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-588
16. Johnston S, Trudeau M, Kaufman B, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26:1066-1072
17. Fayers P, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 scoring manual. Brussels: EORTC Publications, 1997
18. Cleeland CS. Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138
19. Cleeland CS, Nakamura Y, Mendoza TR, et al. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 1996;67:267-273
20. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16:139-144
21. Norman GR, Wyrwich KW, Sloan JA. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592
22. Atherton PJ, Novotny PJ, Jasperson B, et al. So what happened to all the patients? Event charts for summarizing clinically significant changes in oncology quality of life data. Proc Am Soc Clin Oncol 2001;20:abstr 1590. Available at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmviewabst-detail-view &confID10&abstractID1590. [Last accessed 22 May 2009]
23. Hobday TJ, Kugler JW, Mahoney MR, et al. Efficacy and quality of life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol 2002; 20:4574-4580
24. Crown JP, Burris III HA, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008; 12:317-325
25. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008;27:32
26. Seidman AD, Portenoy R, Yao TJ, et al. Quality of life in phase II trials-a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel, plus granulocyte colony stimulating factor. J Natl Cancer Inst 1995;187:1316-1322
27. Shimozuma K, Sonoo H, Ichihara K, et al. The prognostic value of quality of life scores: preliminary results of an analysis of patients with breast cancer. Surg Today 2000;30:255-261